Introduction Monoclonal antibodies (mAbs) should be administered by inhalation rather than
parenterally to improve their efficiency in lung diseases. However, the pulmonary …

Background COVID-19 severity is associated with its respiratory manifestations. Neutralising
antibodies against SARS-CoV-2 administered systemically have shown clinical efficacy …

Monoclonal antibody-based therapeutics have achieved remarkable success in treating a
wide range of human diseases. However, conventional systemic delivery methods have …

Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for
combating respiratory viral infections. However, the effectiveness of neutralising mAb has …

The advent of biologics has brought renewed hope for patients with severe asthma, a
condition notorious for being hampered by poor response to conventional therapies and …

Antibody with high affinity and specificity to antigen has widely used as a tool to combat
various diseases. The variable domain of immunoglobulin new antigen receptor (VNAR) …

Immunoglobulin A (IgA) is the most abundant antibody (Ab) in human mucosae, with
secretory form (sIgA) being dominant and uniquely stable. sIgA is challenging to produce …

Antimicrobial peptides and proteins (APPs) are gaining attraction as powerful agents against
multidrug-resistant bacteria. The inhalation delivery of APPs has emerged as a potent tool …

Many respiratory infections have epidemic and pandemic potential, as evidenced by
influenza and the recent COVID-19 pandemic. Vaccination is an established and effective …

Respiratory viral infections, including influenza, respiratory syncytial virus (RSV), and, more
recently, the coronavirus disease 2019 (COVID-19) pandemic, continue to pose significant …